Search Results - "Buse, J. B."

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) by Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., Matthews, D. R.

Get full text

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes by Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.

“…The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the…”
Get full text

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy : A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes by NATHAN, D. M, BUSE, J. B, DAVIDSON, M. B, HEINE, R. J, HOLMAN, R. R, SHERWIN, R, ZINMAN, B

Get full text

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial by Bode, B. W., Buse, J. B., Fisher, M., Garg, S. K., Marre, M., Merker, L., Renard, E., Russell-Jones, D. L., Hansen, C. T., Rana, A., Heller, S. R.

“…Aims The goal of this study was to compare the long‐term safety and efficacy of the basal insulin analogue, insulin degludec with insulin glargine (both with…”
Get full text

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study by Gokhale, M., Buse, J. B., Gray, C. L., Pate, V., Marquis, M. A., Stürmer, T.

“…Aim To compare pancreatic cancer incidence and diagnostic evaluation among patients initiating dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor treatment with those…”
Get full text

Is insulin the most effective injectable antihyperglycaemic therapy? by Buse, J. B., Peters, A., Russell-Jones, D., Furber, S., Donsmark, M., Han, J., MacConell, L., Maggs, D., Diamant, M.

“…Aims The recent type 2 diabetes American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) position statement suggested insulin is…”
Get full text

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study by Schmidt, W. E., Christiansen, J. S., Hammer, M., Zychma, M. J., Buse, J. B.

“…Diabet. Med. 28, 715–723 (2011) Aims  The Liraglutide Effect and Action in Diabetes 6 trial was an open‐label trial comparing liraglutide with exenatide as an…”
Get full text

dead heat: target normal glucose levels in the intensive care unit--but with caution by Buse, J. B

Get full text

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes by Buse, J. B., Tan, M. H., Prince, M. J., Erickson, P. P.

“…Aim:  Patients with type 2 diabetes often have dyslipidaemia, putting them at risk of cardiovascular disease, and are frequently treated with oral…”
Get full text

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial by Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Zacho, M., Reiter, P. D., Buse, J. B.

“…Aims To confirm, in a 26‐week extension study, the sustained efficacy and safety of a fixed combination of insulin degludec and liraglutide (IDegLira) compared…”
Get full text

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial by Bode, B W, Buse, J B, Fisher, M, Garg, S K, Marre, M, Merker, L, Renard, E, Russell-Jones, D L, Hansen, C T, Rana, A, Heller, S R

“…The goal of this study was to compare the long-term safety and efficacy of the basal insulin analogue, insulin degludec with insulin glargine (both with…”
Get full text

Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues by Fukumoto, H, Kayano, T, Buse, J B, Edwards, Y, Pilch, P F, Bell, G I, Seino, S

“…Complementary DNA clones encoding a facilitative glucose transporter-like protein have been isolated from human small intestine and muscle cDNA libraries. This…”
Get full text

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes by Rodbard, H. W., Buse, J. B., Woo, V., Vilsbøll, T., Langbakke, I. H., Kvist, K., Gough, S. C. L.

“…Aim To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon‐like peptide‐1 receptor agonist,…”
Get full text

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones by Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.

Get full text

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study by Bonds, Denise E, Miller, Michael E, Bergenstal, Richard M, Buse, John B, Byington, Robert P, Cutler, Jeff A, Dudl, R James, Ismail-Beigi, Faramarz, Kimel, Angela R, Hoogwerf, Byron, Horowitz, Karen R, Savage, Peter J, Seaquist, Elizabeth R, Simmons, Debra L, Sivitz, William I, Speril-Hillen, Joann M, Sweeney, Mary Ellen

“…Objective To determine whether there is a link between hypoglycaemia and mortality among participants in the Action to Control Cardiovascular Risk in Diabetes…”
Get full text

Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11–14 year olds: The HEALTHY Study by Jago, R, Drews, K L, Otvos, J D, Willi, S M, Buse, J B

“…Background: GlycA is a novel serum marker of systemic inflammation. There is no information on GlycA in pediatric populations, how it differs by gender or its…”
Get full text

Human intestinal glucose transporter expression and localization of GLUT5 by Davidson, N O, Hausman, A M, Ifkovits, C A, Buse, J B, Gould, G W, Burant, C F, Bell, G I

“…We have studied the developmental and regional expression of mRNAs encoding sodium-dependent and facilitative glucose transporter proteins in human fetal and…”
Get full text

Molecular biology of mammalian glucose transporters by Bell, G I, Kayano, T, Buse, J B, Burant, C F, Takeda, J, Lin, D, Fukumoto, H, Seino, S

“…Molecular biology of mammalian glucose transporters. G I Bell , T Kayano , J B Buse , C F Burant , J Takeda , D Lin , H Fukumoto and S Seino Howard Hughes…”
Get full text

Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials by Seshasai, S. R. K., Bennett, R. L., Petrie, J. R., Bengus, M., Ekman, S., Dixon, M., Herz, M., Buse, J. B., Ray, K. K.

“…Aims To study the short‐term cardiovascular effects of the once‐weekly glucagon‐like peptide‐1 receptor agonist taspoglutide. Methods We conducted a…”
Get full text

Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes by Garg, S. K., Buse, J. B., Skyler, J. S., Vaughn, D. E., Muchmore, D. B.

“…Aims Prandial treatment with human regular insulin for diabetes may result in early postprandial hyperglycaemia and late hypoglycaemia due to its slow onset…”
Get full text